Compare
Qiagen N.V. vs Moderna, Inc. vs Halozyme Therapeutics, Inc. vs Bio-Techne Corp
| Latest fiscal year | Qiagen N.V. QGEN | Moderna, Inc. MRNA | Halozyme Therapeutics, Inc. HALO | Bio-Techne Corp TECH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $2.09B | $1.94B | $1.40B | $1.22B |
| Revenue growth (YoY) | +5.7% | -39.9% | +37.6% | -0.4% |
| Gross margin | 62.2% | 55.3% (computed) | 83.6% (computed) | 65.8% |
| Operating margin | 22.3% | -158.1% | 33.6% | 20.7% |
| Net margin | 20.3% | -145.2% | 22.7% | 15.0% |
| Net income | $424.88M | -$2.82B | $316.89M | $181.86M |
| EPS (Diluted) | $1.94 | -$7.26 | $2.56 | $1.16 |
| Operating cash flow | $654.33M | -$1.87B | $651.56M | $292.07M |
| Free cash flow | $453.28M | -$2.06B | $644.59M | $263.22M |
| Cash & equivalents | $839.00M | $2.60B | $133.82M | $264.71M |
| Total assets | $6.28B | $12.34B | $2.53B | $2.59B |
| Total liabilities | n/a | $3.69B | $2.48B | n/a |
| Shareholders' equity | $3.78B | $8.65B | $48.81M | $2.11B |
| Return on year-end equity | 11.2% | -32.6% | 649.2% | 8.6% |
| Shares outstanding | n/a | 394.00M | 117.78M | 156.10M |
Revenue, most recent five fiscal years
| Fiscal year | Qiagen N.V. | Moderna, Inc. | Halozyme Therapeutics, Inc. | Bio-Techne Corp |
|---|---|---|---|---|
| Latest | $2.09B Ended 2025-12-31 | $1.94B Ended 2025-12-31 | $1.40B Ended 2025-12-31 | $1.22B Ended 2026-06-30 |
| 1 year earlier | $1.98B Ended 2024-12-31 | $3.24B Ended 2024-12-31 | $1.02B Ended 2024-12-31 | $1.22B Ended 2025-06-30 |
| 2 years earlier | $1.97B Ended 2023-12-31 | $6.85B Ended 2023-12-31 | $829.25M Ended 2023-12-31 | $1.16B Ended 2024-06-30 |
| 3 years earlier | $2.14B Ended 2022-12-31 | $19.26B Ended 2022-12-31 | $660.12M Ended 2022-12-31 | $1.14B Ended 2023-06-30 |
| 4 years earlier | $2.25B Ended 2021-12-31 | $18.47B Ended 2021-12-31 | $443.31M Ended 2021-12-31 | $1.11B Ended 2022-06-30 |